

---

# Index

---

## **Account of profits**

- equitable compensation distinguished, 375-376
- exemplary damages, as, 436-439
- loss of opportunity/chance, 376
- onus of proof, 439

## **Administrative Appeals Tribunal (AAT)**

- persona designata exception, 44

## **Airline alliance (Qantas and Air NZ)**

- antitrust issues, 64-69, 305-311

## **Ambush marketing**

- Ansett v Qantas*, 399
- definition, 397-398
- Melbourne 2006 Commonwealth Games (Indicia and Images) Protection Act 2005, 400
- remedies against, 398
- sponsorship cases, 399
- TPA remedies, 398-399

## **Anticompetitive conduct**

- authorisation of *see* **Authorisation proceedings**

## **Antitrust assessments**

- USA v Oracle Corporation* *see* **USA v Oracle Corporation**

## **Arrest of surrogate ships**

- ownership issues
  - Admiralty Act 1988, 312-313, 316
  - Arrest Convention, 313-314
  - English legislation, 314-315
  - Maria Luisa* decisions, 316-319
- nexus, 312

## **Australian Competition and Consumer Commission (ACCC)**

- authorisations in health care markets, 423-427

## **Australian Competition Tribunal (ACT)**

- authorisations in health care markets, 423-427
- establishment, 36
- membership, 36
- role of, 36
- separation of powers, 41-43

## **Authorisation proceedings**

- anticompetitive detriment, 308-310
  - public benefit, 310
- health care markets, in, 423-427
  - onus of proof, 423
- Qantas case*, 305-311
  - foreign shareholders, benefits to, 307

## Index

---

- quantification of benefits, 307-308
- tests for, 305-306
- total welfare standard, 306-307

### **Bannerman, Ron**

- TPC Chairman, 475, 477-478

### **Baxt, Bob**

- TPC Chairman, 475

### **Biodiscovery legislation, 149**

#### **Biodiscovery Act 2004 (Qld)**

- analysis, 148-149
- background, 146-147
- criticisms, 148
- operation, 147-148

### **Book reviews**

- Australian Corporations Legislation* series, 156
- Competition Law in Australia* by SG Corones, 157
- Equity, Restitution and Fraud* by J Glover, 158
- International Trade Law, Commentary and Materials* by M Pryles, J Waincymer, and M Davies, 159

### **Breach of contract**

- exemplary damages, unavailability of, 443-444

### **Bundling**

- ACCC v Baxter*, 485-489
- advantages, 191
- anticompetitive effects of, 30, 194-195
- case law, 194
- competition, effects on, 32-34, 191-192
- consequences of, 30
- definition, 190
- economic theories on, 196-200
- entry barrier, as an, 33-34
- examples of, 191
- exclusionary, 196-200
- exclusive dealing, 193
- misuse of market power, 192-194
- mixed, 190
- predatory pricing, 33-34
- price discrimination, for, 32-33
- pure, 190
- regulation of, 35
- socially efficient, 31-32
- soft drink market, in the, 195

telecommunications market, in the, 195  
United Kingdom's position, 202-203  
United States' position, 200-204  
what is, 30-31, 190

**Carriage of goods**

international, by sea *see* **International carriage of goods by sea**

**Causation**

equitable compensation, 381-385

**Civil penalties**

insider trading, for, 301-304

**Collective bargaining**

health care markets, in, 424

**Commercial contracts**

good faith, obligations of *see* **Good faith in commercial contracts**

**Commonwealth Games**

ambush marketing, 397-400  
Melbourne 2006  
legislation, 400

**Compensation**

equitable *see* **Equitable compensation**

**Competition**

anticompetitive detriment  
*Qantas case*, 308-310  
book review, 157  
bundling, anticompetitive effects of, 30-35, 191-192, 194-195  
consumer protection and, 51-54  
health care markets, 417-422  
test, 417-418  
Hilmer Committee report, 10-11  
IPCR Committee review, 14-15  
National Competition Council review, 12-14  
policy review, 10-11  
software industry, in *see* **USA v Oracle Corporation**  
substantial lessening of  
airline alliance (Qantas and Air NZ), 65  
unconscionability and, 113-115, 125-129

**Competition Principles Agreement (CPA)**

intellectual property review, 10-11  
patent privileges, 8-9

**Compliance committees**

centralisation, 179-181  
costs, 185-187

## Index

---

- establishment, 170-171
- functions, 171-176
- interaction with board, 178-179
- members, 176
  - background and experience, 177-178
  - tenure of, 177
- prevalence, 171
- reporting, 171-172
- research findings, 188-189
- role, 170
- size, 178

### **Consumer credit contracts**

- disclosure obligations
  - predatory lending, 235-237
  - ordinarily prudent consumer test, 238-239
- regulation, 238

### **Consumer protection**

- competition and, 51-54
- National Competition Policy, Productivity Commission report, 51-54
- regulation, 52-53

### **Contract**

- breach of
  - concurrent liability with s 52 TPA *see* **Misleading or deceptive conduct**
  - good faith, obligation of *see* **Good faith in commercial contracts**

### **Contractual interference**

- justification defence, 142-145

### **Contributory negligence**

- equitable compensation, 386-388

### **Corporations**

- legislation series, book review, 156

### **Crown immunity**

- ACCC v Baxter*, 486-489

### **Damages**

- breach of fiduciary duty, for, 390-391
- equitable compensation distinguished, 379-380
- exemplary *see* **Exemplary damages**
- misleading or deceptive conduct, for, 251-252

### **Dawson Report**

- taking advantage of market power, 340-341

### **Disclosure obligations**

- consumer credit contracts
  - predatory lending, 235-237

ordinarily prudent consumer test, 238-239  
Uniform Consumer Credit Code, 235-237

## **Employment**

bargaining agent's fee, claim for, 56-57  
certified agreements, validity of, 61-62  
industrial action, legal status of, 62-63  
relationship, what pertains to, *Electrolux case*, 55-63

## **Equity**

book review, 158  
breach of fiduciary duty, exemplary damages for *see* **Exemplary damages for breach of fiduciary duty**  
equitable compensation *see* **Equitable compensation**

## **Equitable compensation**

accessory liability, 377  
account of profits distinguished, 375-376  
advantages of remedy, 369  
assessment, 378  
availability, 370-371  
*Brickenden* principle, 385-386  
categories, 373-374  
causation, 381-385  
contributory negligence, 386-388  
damages distinguished, 379-380  
exemplary compensation, 390-391  
fiduciary relationship, 370-371  
flexibility of remedy, 380  
interest awards, 390  
limitation of actions, 391  
loss of opportunity/chance, 376-377  
material non-disclosure, 385-386  
mitigation of loss, 388-389  
object, 372  
proprietary relief distinguished, 372-375  
punitive damages, 390-391  
remoteness, 381-384  
reparative compensation, 371  
solicitors, trust account obligations, 389-390  
specific restitution distinguished, 373  
substitutive compensation, 371  
tracing distinguished, 373-374  
types, 371-372  
*Youyang's case*, 389-390

**Exclusion clauses**

- misleading or deceptive conduct, 250
- public policy considerations, 250-251

**Exclusive dealing (s 47 TPA)**

- ACCC v Baxter*, 485-489
- legislative provisions, 193

**Exemplary damages**

- breach of fiduciary duty, for *see* **Exemplary damages for breach of fiduciary duty**
- contract, breach of, availability of remedy, 443-444
- deterrence element, 431-432
- objections to, 433-435
- private law, in, 433-435
- punishment, aim of, 431
- purposes of, 430-433
- tort, availability of remedy in, 444-445
- vindication, role of, 433
- what are, 429

**Exemplary damages for breach of fiduciary duty**

- account of profits, 436-439
  - onus of proof, 439
- allowance for work and skill, 438-439
- availability of, 435-443, 446
- contract, breach of, availability of remedy, 443-444
- election of remedies, 441-442
- interest on awards, 439-440
- tort, availability of remedy in, 444-445

**Evidence**

- antitrust assessments, in *see* **USA v Oracle Corporation**
- misleading representations, of, 263-267

**Fairness**

- unconscionability and, 114-115, 123-124, 129-136

**Fels, Allan**

- TPC Chairman, 474

**Fiduciary duties**

- breach of
  - account of profits, 436-439
  - allowance for work and skill, 438-439
  - election of remedies, 441-442
  - exemplary damages *see* **Exemplary damages for breach of fiduciary duty**
  - injunctions, 441

**Fiduciary relationships**

- equitable compensation, 370-371

exemplary damages for breach of duty *see* **Exemplary damages for breach of fiduciary duty**

**Foreign organisations**

privacy protection for, 50

**Franchise agreements**

business format, 208

business judgment approach, 212-214

disputes

termination, 219-220

territory, 220-222

types of, 211-214

*Dymocks case*, 292-293

termination issues, 293-295, 297-298

good faith obligations, 97, 296-297

case law, 214-217

implications for franchisors, 217-219

termination disputes, 219-220

territory disputes, 220-222

increase in, 208

relational contracts, 290, 295, 298-300

influence of, 296-298

model, 291-292

termination, 297-298

relationship between parties, 209-211, 295

statistics, 208

termination disputes, 219-220

*Dymocks case*, 293-295, 297-298

territory disputes, 220-222

**Fraud**

book review, 158

**Good faith in commercial contracts**

common law obligation, concerns regarding, 88-89

franchise agreements *see* **Franchise agreements**

implied obligation, 90

case studies, 90-92

requirements, 93-94

scope, 95-98

predatory lending, 238

relational contracts, 94

**Health care markets**

agency relationships, 409

authorisations in, 423-427

## Index

---

- onus of proof, 423
- collective bargaining rights, 424
- competition analysis, 417-422
  - test, 417-418
- market definition, 411-417
  - geographic markets, 415-416
  - product markets, 412-415
  - public/private providers, 416-417
  - purposive approach, 411-412
  - SSNIP test, 412-414
- market failure, 408-411
- Medicare, 409-410
- mergers, authorisation of, 427
- misuse of market power, 422-423
- Pharmaceutical Benefits Scheme, 410

### **Hilmer Committee**

- intellectual property review, 10-11

### **Injunctions**

- criminal conduct, to restrain, 441

### **Insider trading**

- civil penalties, imposition of, 301-304
- criminal offence, 301

### **Intellectual property**

- compulsory licensing (s 46 TPA), 155
- Hilmer Committee review, 10-11
- IPCR Committee, review of legislation, 14-15
- National Competition Council review, 12-14
- patent privileges *see* **Patent privileges**
- review of legislation, 10-11

### **Intellectual Property and Competition Review (IPCR) Committee**

- competition, review of, 14-15
- parallel import restrictions, 19-21
- patent privileges, 16-19
  - prospect theory, 17
  - reward theory, 17
- patents, review of, 15-17
- review of intellectual property legislation, 14-15
- TRIPs Agreement, 18

### **Interest**

- equitable compensation claims, 390

### **International carriage of goods by sea**

- conventions relating to, 70



UNCITRAL Draft Instrument, 70, 79-80

aims and objectives, 71

application, 72

arbitration, 78-79

Carriage of Goods by Sea Act 1991, comparison with, 71-79

electronic communication, 77

jurisdiction, 78

liability regime, 74-77

performing party, concept of, 74

period of responsibility, 73-74

scope of, 71-73

transfer of rights, 77-78

uniformity, need for, 70

### **International trade**

book review, 159

### **Limitation of actions**

equitable compensation, 391

### **McComas, Bob**

TPC Chairman, as, interview, 475-484

### **Managed investments**

compliance committees *see* **Compliance committees**

industry, 167

ABS data, 169

ASIC data, 170

outsourcing, 181-185

custodial arrangements, 183-185

investment management, 185

key areas, 181

prescribed investments regime, 181

registered schemes, 167-168

research, 168

regulation, 167

single responsible entity approach, 181

### **Market**

barriers to entry, 345-349

behavioural, 348

structural, 346-348

definition *see* **Market definition**

health care *see* **Health care markets**

### **Market definition**, 345, 474

health care, in, 411-417

## Index

---

- geographic markets, 415-416
- product markets, 412-415
- public/private providers, 416-417
- purposive approach, 411-412
- SSNIP test, 412-414

- SSNIP test, 412-414

- US Merger Guidelines, 450

- USA, in, 450

- USA v Oracle Corporation*

- customer market, 454

- geographic area, 454-455

- product market, 453

- vendor market, 454

### **Market power**

- behavioural indicators of, 352-353

- financial power, 350-351

- misuse of *see* **Misuse of market power**

- sources, 345-352

- barriers to entry, 345-349

- financial power, 350-351

- independent conduct, inhibiting, 350

- market share, 349

- vertical integration, 350

- substantial, 344-345

- vertical integration, 350

- what is, 192

### **Marketing**

- ambush, 397-400

### **Medical practitioners**

- training, regulation of, 426

### **Medicare**

- operation of, 409-410

### **Mergers**

- Guidelines, 450

- health care, in

- authorisation of, 427

- price elevation test, 450-451

- QCM* test, 450-451

- substantial lessening of competition, 452

- unilateral effects, 452-453

- US Merger Guidelines, 450-451

- efficiencies defence, 453

- USA v Oracle Corporation*, 448-474

**Misleading or deceptive conduct (s 52 TPA)**

- conduct, what constitutes
  - contractual promises, 255-259
  - implied contractual provisions, 257
  - making a contract, 253-254
  - pre-contractual representations, 259
- damages (s 82), 251-252
- exclusion clauses, 250
  - public policy considerations, 250-251
- legislative provisions, 249
- liability for breach, 266-267
  - contractual liability compared, 253
  - new rule, 275-277
  - public policy concerns, 279-282
  - resolution, suggestions for, 282-287
  - s 68A, 277-278
- remedies
  - damages (s 82), 251-252
  - s 87, 252-253
- representations as to future events (s 51A), 260
  - application, 267-268
  - consequences, 268
  - evidence required, 263-267
  - implied representations, 261, 265
  - prediction cases, 264, 265
  - present belief/ability/intent, representation of, 261-264
  - subjective intent, 265, 267, 273
  - time evidence to be judged, 263
  - Unisys v RACV*, 272-274
- Unisys v RACV*
  - alleged representations, 270, 272-274
  - conclusions to be drawn from, 274-275
  - contractually agreed delivery date, 271-272
  - decision, 271
  - facts, 269

**Misleading representations (s 51A TPA)**

- future events, as to, 260
  - application, 267-268
  - consequences, 268
  - evidence required, 263-267
  - implied representations, 261, 265
  - prediction cases, 264, 265
  - present belief/ability/intent, representation of, 261-264

## Index

---

subjective intent, 265, 267, 273  
time evidence to be judged, 263  
*Unisys v RACV*, 272-274

### **Misuse of market power (s 46 TPA)**

*ACCC v Baxter*, 485-489  
access regime, 154-155  
bundling, 192-194  
“carrying on a business”, 151-152  
elements, 327  
health care markets, in, 422-423  
legislative provisions, 126-127, 192  
leveraging, 150  
*NT Power Generation v PAWA*, 150-155  
object of, 343  
taking advantage, 327-368  
*ACCC v Baxter*, 485-489  
    *Boral* decisions, 334-336  
    counterfactual approach, 355-367  
    Dawson Report, 340-341  
    *Dowling v Dalgety*, 362  
    materially facilitate test, 332  
    *Melway* cases, 330-334, 363  
    objective test, 355  
    *PAWA*, 339-340, 366-367  
    *Queensland Wire case*, 329-230, 361-362  
    rational business explanation, 333-336  
    *Rural Press*, 336-337, 363-365  
    *Safeway case*, 338-339  
    Senate Report, 340-341  
    use test, 330  
vertically integrated corporations, 150-155

### **Mitigation of loss**

equitable compensation, 388-389

### **National Competition Council (NCC)**

intellectual property review, 12-14  
Terms of Reference, 12

### **National Competition Policy**

Productivity Commission report, 51-54

### **National Privacy Principles**

breach, 46  
    standing, 45, 47  
interpretation, 47-48

**New Zealand**

- airline alliance (Air NZ and Qantas)
  - appeal, 64-65
  - authorisation proceedings, 305-311
  - background, 64
  - competition analysis, 65
  - domestic main-trunk market, 66
  - public benefit, 67
  - public detriment, 66-67

**Parallel imports**

- restrictions in copyright legislation, 19-21

**Patent privileges**

- benefit threshold, 21-25
- Competition Principles Agreement, 8-9
- IPCR Committee, 16-19
  - prospect theory, 17
  - reward theory, 17
- National Competition Policy, 9
- public interest test, 25-28
- Regulatory Impact Statements, 22-24

**Persona designata doctrine**

- Australian Competition Tribunal, application to, 41-43
- separation of powers, 39
  - incompatibility condition, 40
  - public confidence incompatibility, 40-41

**Pharmaceutical Benefits Scheme (PBS)**

- operation of, 410

**Predatory lending**

- Community Development Finance programs, 227
- disclosure requirements, 235-237
  - ordinarily prudent consumer test, 238-239
- effect of, 224
- financial vulnerability, 225, 228-231
  - nature and experiences of, 231-234
  - policy responses to, 234-239
- good faith obligations, 238
- history, 225-228
- responses to, 225-228, 234-239
- Uniform Consumer Credit Code, disclosure requirements, 235-237
- what is, 225

**Predatory pricing**

- bundling and, 33-34

## Index

---

what is, 191

### **Privacy**

enforcement procedure, 49

foreign organisations, 50

industry codes, 49

Internet Industry Association code, 49

National Privacy Principles

breach, 46

interpretation, 47-48

standing, 45, 47

*Seven Network case*, 45-50

implications for business, 48

### **Queensland**

Biodiscovery Act 2004, 146-149

### **Quistclose trusts**

operation, 392

resulting trusts, 392-396

automatic, 392

presumed, 393

### **Remoteness**

equitable compensation, 381-384

### **Restitution**

book review, 158

### **Resulting trusts**, 392-396

### **Retail tenancies**

unconscionability, application to, 136-140

### **Senate Report**

taking advantage of market power, 340-341

### **Separation of powers**

Australian Competition Tribunal, 41-43

*Boilermakers'* principle, 39

general principles, 36-37

persona designata exception, 39

incompatibility condition, 40

public confidence incompatibility, 40-41

*Tasmanian Breweries case*, 37-38

### **Software industry**

competition in *see* **USA v Oracle Corporation**

### **Solicitors**

trust account obligations, equitable compensation, 389-390

**Special disadvantage**

unconscionability, 103-107, 137-139

**Substantial lessening of competition**

airline alliance (Qantas and Air NZ), 65

mergers, 452

unilateral effects, 452-453

**Surgeons**

training, regulation of, 426-427

**Surrogate ships**

arresting *see* **Arrest of surrogate ships**

**Tort**

exemplary damages, availability of remedy for breach, 444-445

**Tracing**

equitable remedy, 373-374

**Trade Practices Commission (TPC)**

Bannerman, Ron, 475, 477-478

Baxt, Bob, 475

Chairmen of, 475-484

Fels, Allan, 474

McComas, Bob, 475-484

**TRIPs Agreement**

patent threshold requirements, 18

**Trust accounts**

solicitors' obligations, equitable compensation, 389-390

**Tying**

what is, 31, 190

**UNCITRAL Draft Instrument on Transport Law *see* International carriage of goods by sea****Unconscionability**

*ACCC v Berbatis*, 102-107

competition and, 113-115, 125-129

concept of, 102-103, 119-122

economic efficiency, 129-136

fairness and, 114-115, 123-124, 129-136

legislative provisions (Pt IVA TPA), 100-101, 107, 122-124

consistency in interpretation, 115-119

matters court may consider, 120

misuse of market power, 126-127

relationship of trust and confidence, 125-129

retail tenancies, application to, 136-140

special disadvantage, 103-107, 137-139

unwritten law, 107-113, 122-124

**Uniform Consumer Credit Code**

- consumer credit contracts, regulation of, 238
- disclosure requirements, 235-237

**United Kingdom**

- bundling case law, 202-203

**United States**

- bundling case law, 200-204
- Merger Guidelines, 450-451
  - efficiencies defence, 453

**USA v Oracle Corporation**, 448-474

- consultant witnesses, 456-457
- customer evidence, 455-456
  - difficulties with, 462-468
- expert evidence, 458-461, 468-473
  - Elzinga, 458-460
  - Iansiti, 458
  - industry evidence and, 473-474
  - McAfee, 460-461
  - quantitative vs qualitative, 469-471
- industry evidence, 455-458, 461-462
  - expert evidence and, 473-474
- markets, establishment of
  - customer market, 454
  - geographic area, 454-455
  - product market, 453
  - vendor market, 454
- vendor witnesses, 456-457